Last reviewed · How we verify

Contrast Ultrasound

Rabih A. Chaer · Phase 2 active Small molecule

Contrast Ultrasound is a Small molecule drug developed by Rabih A. Chaer. It is currently in Phase 2 development. Also known as: Definity.

At a glance

Generic nameContrast Ultrasound
Also known asDefinity
SponsorRabih A. Chaer
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Contrast Ultrasound

What is Contrast Ultrasound?

Contrast Ultrasound is a Small molecule drug developed by Rabih A. Chaer.

Who makes Contrast Ultrasound?

Contrast Ultrasound is developed by Rabih A. Chaer (see full Rabih A. Chaer pipeline at /company/rabih-a-chaer).

Is Contrast Ultrasound also known as anything else?

Contrast Ultrasound is also known as Definity.

What development phase is Contrast Ultrasound in?

Contrast Ultrasound is in Phase 2.

Related